PEB
18/03/2015 10:30
GENERAL
NOT PRICE SENSITIVE
REL: 1030 HRS Pacific Edge Limited
GENERAL: PEB: Cxbladder Triage to be showcased in prestigious med journal
18 March 2015
Cxbladder Triage to be showcased in prestigious medical journal
Dunedin-based Pacific Edge will gain a global audience for one of its newest
products after the internationally acclaimed medical journal BioMed Central
("BMC") Urology accepted for publication the science paper describing the
clinical performance of its recently launched bladder cancer test Cxbladder
Triage.
BMC is a Science, Technology and Medicine publisher of 276 peer-reviewed open
access journals. The journal views open access to research as essential in
order to ensure the rapid and efficient communication of research findings.
Publication is expected later this month after acceptance was granted for the
publication of the performance and science behind Cxbladder Triage. Pacific
Edge Chief Executive Officer David Darling says: "Publication in BMC is an
effective and efficient way of reaching the clinicians who make treatment
decisions for patients and for the executives of the payer organisations and
healthcare providers who fund such medical devices. It is a key element in
our strategy of making the product available in the USA this year."
Cxbladder Triage, the second product in its suite of proprietary molecular
tests for the detection and management of bladder cancer, was launched at the
end of last year in New Zealand. It takes us a step closer to our vision of
the suite of Cxbladder products becoming a 'one-stop-shop' for bladder cancer
detection and management for the clinicians and physicians," says David
Darling.
Cxbladder Triage complements the first molecular diagnostic test Cxbladder
Detect and will enable clinicians and physicians to accurately segregate
patients who present with blood in their urine (haematuria), who have a low
probability of having bladder cancer. Potentially this will save many
patients from undergoing an expensive and invasive investigation for bladder
cancer and enable clinicians to make effective choices about the deployment
of their skills and capabilities on the patients who need it most.
The Commercial Director for Pacific Edge Diagnostics NZ, Brent Pownall
says:"Cxbladder Triage is a new weapon against cancer in the armoury of both
clinicians and physicians and compliments naturally Cxbladder Detect, the
company's detection technology. Cxbladder Triage enables clinicians and
physicians to evaluate patients presenting with haematuria, to quickly and
accurately remove those who have a low probability of having a urothelial
carcinoma, thereby lowering the number that are likely to need a full
urological work-up."
"Cxbladder Triage is a non-invasive laboratory test used primarily to rule
out the presence of bladder cancer quickly, easily and painlessly, giving
greater peace of mind to both patients and clinicians. In New Zealand,
Cxbladder Triage is targeted to empower all physicians evaluating patients
with haematuria in the primary care setting," says Brent Pownall. ."
For more information contact:
David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800
ABOUT PACIFIC EDGE
Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
company specialising in the discovery and commercialisation of diagnostic and
prognostic technology for the early detection and monitoring of cancer. The
company is developing and commercialising its range of Cxbladder bladder
cancer tests. It's first commercial product, Cxbladder Detect, is now being
actively marketed to physicians and clinicians in New Zealand, Australia, and
the USA through the company's wholly owned subsidiaries and selected
commercial partners.
www.pacificedge.co.nz www.pacificedgedx.com
ABOUT Cxbladder Detect
Cxbladder Detect is a proprietary, accurate molecular diagnostic test that
enables the non-invasive detection of bladder and other urinary tract cancers
from a small volume of urine. Cxbladder Detect is commercially available in
New Zealand, Australia and the USA. Cxbladder Detect is available in the USA
and NZ as a laboratory Developed Test (LDT) from the company's CLIA certified
laboratories, providing physicians and clinicians with a quick, cost
effective and accurate measure of the presence of the cancer, and provides
urologists with the opportunity to reduce their reliance on the need for
invasive tests such as cystoscopy. The Cxbladder Detect cancer detection test
has been validated by a multicentre, international clinical study.
www.cxbladder.com
ABOUT Cxbladder Triage
Cxbladder Triage is a novel molecular test that combines the power of the
genomic biomarkers with extra phenotypic biomarkers to accurately identify
and remove patients with haematuria who have a low probability of bladder
cancer, from needing to have a full-urological work-up. This is a tool for
use by clinicians and physicians in the primary evaluation and will result
in a reduction of the number of patients needing an expensive and invasive
work-up for urothelial cancer.
www.cxbladder.com
ABOUT BLADDER CANCER
Globally, bladder cancer has the 9th highest incidence and the 4th highest
incidence for men. One of the early symptoms of bladder cancer is the
presence of blood in the urine, haematuria. People with haematuria often
present to their general practitioner before being referred on to a
urologist.
Bladder cancer has a very high recurrence rate of approximately 50%-70% with
up to 30% of these recurring as later stage tumours. However, bladder cancers
are highly treatable, especially if detected in the early stages when there
is a much higher probability of survival. Timely detection and regular
surveillance and monitoring of this cancer is a key element of the clinical
process and of the individual's annual healthcare plan.
End CA:00262004 For:PEB Type:GENERAL Time:2015-03-18 10:30:38
